This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Benchmark Electronics CEO Discusses Q4 2010 Results - Earnings Call Transcript

During this call, we may make projections or other forward-looking statements regarding future events or the future financial performance of the Company. We’d like to caution you that those statements reflect our current expectations and that actual events or results may differ materially. We also like to refer you to Benchmark’s periodic reports that are filed from time-to-time with the Securities and Exchange Commission, including the Company’s 8-K and S4 filings, quarterly filings and Form 10-Q and our annual report on Form 10-K. These documents contain cautionary language and identify important risk factors which could cause actual results to differ materially from our projections or forward-looking statements. We undertake no obligation to update those projections or forward-looking statements in the future.

Now, I will turn the call over to Cary.

Cary Fu

Thank you, Don. Good morning. Thank you for joining us on our call today. We are very pleased to share with you our results for the year 2010. Overall, 2010 was a very good year for Benchmark. We accomplished a revenue growth of about 15% when compared year 2010 to 2009. Along with the revenue growth, came earnings per shares growth about 52% on a year-over-year basis.

We finished 2010 with a strong Q4. As you can recall through the last conference call, we expect some weakness from our computing customers in fourth quarter. However, the sales to the computing sector pick up late in the quarters were stronger than was originally anticipated. Along with these financial results for the year, Benchmark completed two of our strategic goals.

Number one, medical Class III device capability in Asia. In November, we announced that our Thailand facility had been approved by FDA to manufacture Class III finished device on behalf of our large Tier one medical customers. This is a significant accomplishment that give us medical customers this capability everywhere around the globe.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs